BioCentury | Feb 24, 2021
Deals

Feb. 23 Quick Takes: BGI raises $300M, plus a $230M C round for Clover, Day One, Waksal’s Graviton, Asalyxa

...exclusive, worldwide rights outside of China to TDI01, a targeted inhibitor of ROCK2. Tide, a Sino Biopharmaceutical Ltd....
...containing protein kinase 2 BC Staff NeuroRx Inc. BGI Genomics Co. Ltd. Clover Biopharmaceuticals Day One Biopharmaceuticals LLC Merck KGaA Teon Therapeutics Inc. Sino Biopharmaceutical Ltd. Asalyxa...
BioCentury | Jan 7, 2021
Deals

Jan. 6 Quick Takes:  Ribometrix gets $25M up front in Genentech RNA deal; plus Dewpoint-Pfizer, Kite-Oxford BioTherapeutics, Illumina-Helix and more

...hospital marketGenetron Holdings Ltd. (NASDAQ:GTH) partnered with Sino Biopharmaceutical Ltd....
...Staff Ribometrix Genentech Pfizer Dewpoint Therapeutics Kite Pharma Gilead Oxford BioTherapeutics Illumina Fate Therapeutics Y-Biologics 3D Medicines Corp. Genetron Health Sino Biopharmaceutical...
BioCentury | Dec 23, 2020
Deals

Insilico caps year of deals by opening its computational platforms to pharmas’ in-house teams

...2020 deal partners include Astellas Pharma Inc. (Tokyo:4503), Boehringer Ingelheim GmbH, Pfizer Inc. (NYSE:PFE) and Sino Biopharmaceutical Ltd....
BioCentury | Mar 19, 2020
Product Development

March 18 Quick Takes: Duo of Phase III data for Pfizer; plus Sage, Allergan-AbbVie, Merck, DermTech, Beijing Tide-Insilico

...93% to 97% in patients with skin lesions. Beijing Tide, Insilico partner for cancer therapies Sino Biopharmaceutical Ltd....
BioCentury | Nov 5, 2019
Financial News

Following JV, Sino backs Akeso's $150M series D

...Six months after establishing a joint venture with Akeso, Sino Biopharmaceutical has co-led a series D round...
...targeting PD-1. In June, the Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (CTTQ) subsidiary of Sino Biopharmaceutical Ltd....
BioCentury | Oct 28, 2019
Financial News

After Hong Kong IPO lull, local demand lifts Ascentage offering

...gains, the company ended the day with a market cap of HK$7.8 billion. Cornerstone investor Sino Biopharmaceutical Ltd....
BioCentury | Jun 19, 2019
Company News

June 18 Company Quick Takes: Sino-Akeso JV, plus Oxford Drug Design, Be The Match and more

...to develop PD-1 mAb The Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (CTTQ) subsidiary of Sino Biopharmaceutical Ltd....
...Co. Ltd. Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator Jiangsu Hengrui Medicine Co. Ltd. Kowa Co. Ltd. Merck & Co. Inc. Sino Biopharmaceutical Ltd. TrakCel...
BioCentury | Mar 13, 2019
Politics & Policy

China releases timeline, priority diseases for revised reimbursement list

...drug Bydureon exenatide and cancer drug pyrotinib from Hengrui could be included, and added that Sino Biopharmaceutical Ltd....
...HK$0.32 to HK$13.32. Hongjiang Li, Staff Writer 3SBio Inc. CSPC Pharmaceutical Group Ltd. Innovent Biologics Inc. Jiangsu Hengrui Medicine Co. Ltd. Sino Biopharmaceutical Ltd. China's...
BioCentury | Jan 18, 2019
Politics & Policy

Winners of China's centralized procurement to secure over 60% market share

...have passed equivalence testing. Several tender winners saw gains on Friday following the program’s approval. Sino Biopharmaceutical Ltd....
...and Shenzhen Salubris Pharmaceuticals Co. Ltd. (SZSE:002294) added RMB0.45 to RMB21.20. Hongjiang Li Shenzhen Salubris Pharmaceuticals Co. Ltd. Sino Biopharmaceutical Ltd. Zhejiang...
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
Items per page:
1 - 10 of 25
BioCentury | Feb 24, 2021
Deals

Feb. 23 Quick Takes: BGI raises $300M, plus a $230M C round for Clover, Day One, Waksal’s Graviton, Asalyxa

...exclusive, worldwide rights outside of China to TDI01, a targeted inhibitor of ROCK2. Tide, a Sino Biopharmaceutical Ltd....
...containing protein kinase 2 BC Staff NeuroRx Inc. BGI Genomics Co. Ltd. Clover Biopharmaceuticals Day One Biopharmaceuticals LLC Merck KGaA Teon Therapeutics Inc. Sino Biopharmaceutical Ltd. Asalyxa...
BioCentury | Jan 7, 2021
Deals

Jan. 6 Quick Takes:  Ribometrix gets $25M up front in Genentech RNA deal; plus Dewpoint-Pfizer, Kite-Oxford BioTherapeutics, Illumina-Helix and more

...hospital marketGenetron Holdings Ltd. (NASDAQ:GTH) partnered with Sino Biopharmaceutical Ltd....
...Staff Ribometrix Genentech Pfizer Dewpoint Therapeutics Kite Pharma Gilead Oxford BioTherapeutics Illumina Fate Therapeutics Y-Biologics 3D Medicines Corp. Genetron Health Sino Biopharmaceutical...
BioCentury | Dec 23, 2020
Deals

Insilico caps year of deals by opening its computational platforms to pharmas’ in-house teams

...2020 deal partners include Astellas Pharma Inc. (Tokyo:4503), Boehringer Ingelheim GmbH, Pfizer Inc. (NYSE:PFE) and Sino Biopharmaceutical Ltd....
BioCentury | Mar 19, 2020
Product Development

March 18 Quick Takes: Duo of Phase III data for Pfizer; plus Sage, Allergan-AbbVie, Merck, DermTech, Beijing Tide-Insilico

...93% to 97% in patients with skin lesions. Beijing Tide, Insilico partner for cancer therapies Sino Biopharmaceutical Ltd....
BioCentury | Nov 5, 2019
Financial News

Following JV, Sino backs Akeso's $150M series D

...Six months after establishing a joint venture with Akeso, Sino Biopharmaceutical has co-led a series D round...
...targeting PD-1. In June, the Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (CTTQ) subsidiary of Sino Biopharmaceutical Ltd....
BioCentury | Oct 28, 2019
Financial News

After Hong Kong IPO lull, local demand lifts Ascentage offering

...gains, the company ended the day with a market cap of HK$7.8 billion. Cornerstone investor Sino Biopharmaceutical Ltd....
BioCentury | Jun 19, 2019
Company News

June 18 Company Quick Takes: Sino-Akeso JV, plus Oxford Drug Design, Be The Match and more

...to develop PD-1 mAb The Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (CTTQ) subsidiary of Sino Biopharmaceutical Ltd....
...Co. Ltd. Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator Jiangsu Hengrui Medicine Co. Ltd. Kowa Co. Ltd. Merck & Co. Inc. Sino Biopharmaceutical Ltd. TrakCel...
BioCentury | Mar 13, 2019
Politics & Policy

China releases timeline, priority diseases for revised reimbursement list

...drug Bydureon exenatide and cancer drug pyrotinib from Hengrui could be included, and added that Sino Biopharmaceutical Ltd....
...HK$0.32 to HK$13.32. Hongjiang Li, Staff Writer 3SBio Inc. CSPC Pharmaceutical Group Ltd. Innovent Biologics Inc. Jiangsu Hengrui Medicine Co. Ltd. Sino Biopharmaceutical Ltd. China's...
BioCentury | Jan 18, 2019
Politics & Policy

Winners of China's centralized procurement to secure over 60% market share

...have passed equivalence testing. Several tender winners saw gains on Friday following the program’s approval. Sino Biopharmaceutical Ltd....
...and Shenzhen Salubris Pharmaceuticals Co. Ltd. (SZSE:002294) added RMB0.45 to RMB21.20. Hongjiang Li Shenzhen Salubris Pharmaceuticals Co. Ltd. Sino Biopharmaceutical Ltd. Zhejiang...
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
Items per page:
1 - 10 of 25